Attached files

file filename
EX-8.1 - EXHIBIT 8.1 - OMEGA HEALTHCARE INVESTORS INCt1500280_ex8-1.htm
EX-1.1 - EXHIBIT 1.1 - OMEGA HEALTHCARE INVESTORS INCt1500280_ex1-1.htm
EX-5.1 - EXHIBIT 5.1 - OMEGA HEALTHCARE INVESTORS INCt1500280_ex5-1.htm
EX-99.1 - EXHIBIT 99.1 - OMEGA HEALTHCARE INVESTORS INCt1500280_ex99-1.htm
EX-99.2 - EXHIBIT 99.2 - OMEGA HEALTHCARE INVESTORS INCt1500280_ex99-2.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 4, 2015

 

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in charter)

 

Maryland 1-11316 38-3041398
(State of incorporation) (Commission File Number)

(IRS Employer

Identification No.)

 

200 International Circle

Suite 3500

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

 

(410) 427-1700

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act.

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

 

 
 

 

Item 8.01. Other Events

 

On February 4, 2015, Omega Healthcare Investors, Inc. (the “Company” or “Omega”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Merrill Lynch, Pierce, Fenner & Smith Incorporation, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Stifel, Nicolaus & Company, Incorporated (the “Representatives”), as representatives of the several underwriters listed therein (the “Underwriters”), in connection with an underwritten public offering of 9,500,000 shares of the Company’s common stock, par value $0.10 per share. In addition, the Company granted to the Underwriters an option to purchase up to an additional 1,425,000 shares to cover over-allotments, which option has since been exercised. Omega’s total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, will be approximately $382,000,000. The offering is expected to close on or about February 9, 2015.

 

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed up by the contracting parties.

 

The offered shares were registered under an existing automatic shelf registration statement on Form S-3 (Registration No. 333-179795) filed by Omega on February 29, 2012 with the Securities and Exchange Commission, including a prospectus supplement dated February 4, 2015 and filed with the Securities and Exchange Commission on February 5, 2015 pursuant to Rule 424(b)(2) under the Act.

 

A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated by reference herein. The foregoing description of the Underwriting Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to such exhibit.

 

Copies of the press releases announcing the offering and announcing the pricing of the offering are attached as Exhibits 99.1 and 99.2, respectively.

 

The estimated expenses in connection with the offering of the shares are approximately $1,000,000 excluding underwriters discounts and commissions.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)         Exhibits

 

Exhibit No. Description of Exhibit
   
1.1 Underwriting Agreement
5.1 Opinion of Bryan Cave LLP regarding the legality of the Common Stock being registered.
8.1 Opinion of Bryan Cave LLP regarding certain tax matters
23.1 Consent of Bryan Cave LLP (contained in Exhibit 5.1)
23.2 Consent of Bryan Cave LLP (contained in Exhibit 8.1)
99.1 Press Release dated February 3, 2015
99.2 Press Release dated February 4, 2015

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OMEGA HEALTHCARE INVESTORS, INC.
  (Registrant)
   
Dated:  February 9, 2015 By:  /s/ Robert O. Stephenson
    Robert O. Stephenson
    Chief Financial Officer and Treasurer

 

3